Yüklüyor......
Chemoproteomics reveals novel protein and lipid kinase targets of clinical CDK4/6 inhibitors in lung cancer
Several selective CDK4/6 inhibitors are in clinical trials for non-small cell lung cancer (NSCLC). Palbociclib (PD0332991) is included in the phase II/III Lung-MAP trial for squamous cell lung carcinoma (LUSQ). We noted differential cellular activity between palbociclib and the structurally related...
Kaydedildi:
| Yayımlandı: | ACS Chem Biol |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4684772/ https://ncbi.nlm.nih.gov/pubmed/26390342 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acschembio.5b00368 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|